Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Osborne CK, Wakeling A, Nicholson RI. · 2004

Read Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. by Osborne CK, Wakeling A, Nicholson RI. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2750773.txt.

Introduction

Osborne, Wakeling, and Nicholson reviewed in 2004 fulvestrant, a new breast cancer drug. It blocks the estrogen receptor and lowers the receptor itself. It has no estrogen-like effects. Hormone therapies are favored for hormone-sensitive metastatic breast cancer because they are well tolerated. Older drugs such as tamoxifen partly mimic estrogen, and cross-resistance limits how long similar drugs can be sequenced.

Their review explains estrogen signaling and how fulvestrant differs. It binds the receptor, blocks it fully, and drives its loss, so receptor levels fall in the cell. Lab and clinical data support that novel mechanism. A drug that is not cross-resistant lets doctors extend tolerated hormone treatment before turning to harsher chemotherapy. Women who still respond to hormone drugs gain more time on gentler care first.

Catalog record

CREATOROsborne CK, Wakeling A, Nicholson RI.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2750773

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action By C K Osborne, A Wakeling, R I Nicholson Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6601629 ABSTRACT Due to their favourable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer. However, the oestrogen agonist effects of the available selective oestrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms. Fulvestrant (‘Faslodex’) is the first of a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. This article provides an overview of the current understanding of ER signalling and illustrates the unique mode of action of fulvestrant. Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist. New hormonal therapies with novel mechanisms of action that are not cross-resistant with the existing treatments make important additions to the repertoire of treatments for breast cancer. This enables additional endocrine agents to be used sequentially, with the aim of extending the effective duration of well-tolerated treatment before cytotoxic chemotherapy becomes necessary (Carlson, 2002). Fulvestrant (‘Faslodex’) is the first of a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. An understanding of ER signalling is essential to distinguish between the mode of action of fulvestrant and that of tamoxifen and the other selective ER modulators (SERMs). This article summarises the current knowledge of oestrogen signalling, and outlines the mechanism of action of fulvestrant. OESTROGEN SIGNALLING AS A TARGET FOR BREAST CANCER THERAPY 17β-oestradiol, the dominant circulating oestrogen, controls the growth of many breast tumours. Oestradiol is secreted by the ovaries in premenopausal women, but is also present at significant levels in postmenopausal breast tumours. In postmenopausal women, oestrogens are produced by aromatase-mediated conversion of androgens (originating from the adrenal glands and the ovaries) to oestrogens, in normal tissues (adipose tissue, muscle, liver, or brain) as well as in breast tumours (Buzdar, 2001). The ER is expressed in the majority of breast tumours (Jonat and Maass, 1978; Lee and Markland, 1978; Paszko et al, 1978) and in a number of endocrine tissues including the normal breast, uterus and vagina, as well as in the pituitary and hypothalamus. Oestradiol binds to the ER with a high affinity and specificity and, once bound, the oestradiol/ER complex can exert its effects at both nuclear and cell membranous sites (Figure 1Figure 1Cellular distribution and activity of the ER. The known mechanisms of fulvestrant intervention in ER signalling are indicated with an asterisk. EGFR=epidermal growth factor receptor; ERE=oestrogen response element; ER=oestrogen receptor.). In the classical nuclear ER pathway of transcriptional control, the binding of oestradiol to the ER initiates dissociation of heat shock proteins from the ER, followed by receptor dimerisation and preferential nuclear localisation (Beato, 1989; MacGregor and Jordan, 1998). The oestrogen–ER dimer complex binds to specific DNA sequences, the oestrogen response elements (EREs), which are situated in the regulatory regions of oestrogen-sensitive genes. Transcriptional control is mediated via two regions of the ER-designated activation functions AF1 and AF2, which recruit other proteins such as transcriptional co-activators and co-repressors to the transcriptional complex (Beato, 1989; Tsai and O'Malley, 1994; Horwitz et al, 1996; White and Parker, 1998). AF1 activity is regulated by growth factors that act via the mitogen-activated protein kinase (MAPK) pathway (Kato et al, 1995), while the AF2 domain is activated by oestrogen (Kumar et al, 1987). Both domains are required to be active for full oestrogen agonist activity. The ER mediates transcriptional regulation of a range of genes, directly or indirectly associated with proliferation, invasion, survival or angiogenesis in breast cancer. To date, two ERs have been identified: the ‘classic’ ERα and the relatively more recently described ERβ (Kuiper et al, 1996). These two ER subtypes have different tissue distributions (Speirs et al, 2002), different affinities and responsiveness to various SERMs (Ogawa et al, 1998), and are under different regulatory control (Katzenellenbogen and Katzenellenbogen, 2000). Oestrogen receptorα rather than ERβ appears to be the predominant regulator of oestrogen-induced genes in breast cancer (Palmieri et al, 2002; Fuqua et al, 2003). In addition to the classical ER signalling pathway, the ER can also undergo ‘crosstalk’ with growth factor and G-protein-coupled signalling pathways (Philips et al, 1993; Losel and Wehling, 2003) (Figure 1). For example, oestrogen can activate membrane-bound ER and, via G-protein activation, can then activate growth factor receptors such as the epidermal growth factor (EGF) receptor and human epidermal growth factor receptor 2 (HER2/neu) (Filardo, 2002; Johnston et al, 2003). In turn, the ER itself may be activated in a ligand-independent manner by other signalling molecules such as growth factors and protein kinases that control the phosphorylation state of the ER complex and play a part in regulating activity of the ER (Katzenellenbogen et al, 2000). THE NEED FOR ALTERNATIVE ENDOCRINE THERAPIES In patients with hormone-sensitive advanced breast cancer, endocrine therapy is better tolerated than cytotoxic chemotherapy, while being equally effective (Buzdar, 2001). However, there are specific risks associated with endocrine treatments. For example, tamoxifen treatment is associated with a 2–4-fold increased risk of endometrial cancer (Early Breast Cancer Trialists' Collaborative Group, 1998), attributable to its oestrogen-like, partial agonist activity. The ‘Arimidex’, Tamoxifen Alone or in Combination (ATAC) trial showed a significantly greater incidence of ischaemic cerebrovascular events (2.1 vs 1.0%; P=0.0006) and venous thromboembolic events (3.5 vs 2.1%; P=0.0006) with tamoxifen, compared with the aromatase inhibitor (AI) anastrozole (ATAC Trialists' Group, 2002). A number of other antioestrogens grouped together under the term SERMS have also been associated with partial agonist properties (Johnston, 2001; Arun et al, 2002). The AIs letrozole and exemestane may have an unfavourable effect on plasma lipid levels, and androgenic side effects have been reported with exemestane (Buzdar, 2003). Megestrol acetate, historically the most widely used progestin, is associated with weight gain and fluid retention (Espie, 1994) and the high-dose oestrogen diethylstilboestrol is commonly associated with nausea, oedema, vaginal bleeding and cardiac problems (Peethambaram et al, 1999). The sequential use of well-tolerated hormonal therapies has become common clinical practice for the treatment of advanced breast cancer, where maintenance of quality of life is a primary aim. For this to be effective, it is necessary that the mechanism of action of newer agents differ from those previously used. This prerequisite prevents the sequential use of therapies belonging to the same class, and that therefore demonstrates cross-resistance with each other. Therefore, for some time, a search has been under way for an antioestrogen that lacks partial agonist properties and that has a mechanism of action different from tamoxifen (Wakeling and Bowler, 1988). FULVESTRANT: A POTENT ER ANTAGONIST WITH A NOVEL MECHANISM OF ACTION Blockade of oestrogen action via ER antagonism Fulvestrant is a 7α-alkylsulphinyl analogue of 17β-oestradiol, which is distinctly different in chemical structure from the nonsteroidal structures of tamoxifen, raloxifene and other SERMs (Figure 2Figure 2Structure of 17β-oestradiol, fulvestrant, tamoxifen and raloxifene.). Fulvestrant competitively inhibits binding of oestradiol to the ER, with a binding affinity that

Read the complete text